This paper outlines the design of a Phase 2 trial investigating clopidogrel for proteinuria reduction in focal segmental glomerulosclerosis, with no clinical results reported.
Does clopidogrel reduce proteinuria in patients with focal segmental glomerulosclerosis?
This paper describes the design of a Phase 2 trial evaluating clopidogrel for proteinuria reduction in focal segmental glomerulosclerosis.
Focal segmental glomerulosclerosis (FSGS) combines a heterogeneous group of different etiologies with defined glomerular histopathology and accounts for approximately 10% of nephrotic syndrome cases in adults and 20% of cases in children in Europe. Currently, there is no specific therapy available for FSGS, with the majority of patients being treated with systemic corticosteroids, calcineurin inhibitors and renin-angiotensin-system (RAS) inhibitors.1 While some patients respond to therapy, a significant proportion remains unresponsive, ultimately requiring kidney replacement therapy, resulting in a significant burden to the individual patient as well as to the health care system.
Daniel-Fischer et al. (Fri,) conducted a other in Focal segmental glomerulosclerosis. Clopidogrel was evaluated on Proteinuria reduction. This paper outlines the design of a Phase 2 trial investigating clopidogrel for proteinuria reduction in focal segmental glomerulosclerosis, with no clinical results reported.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: